Month: May 2025

Advanced Technology International Acquires Carrot

Written by Customer Service on May 13, 2025. Posted in Mergers And Acquisitions.

SUMMERVILLE, S.C., May 13, 2025 (GLOBE NEWSWIRE) — We are excited to announce that effective March 31, 2025, Advanced Technology International (ATI), a South Carolina based 501(c)3 public service nonprofit, acquired the assets of The Common Pool, LLC, dba Carrot. ATI is the Nation’s original and largest Consortium Management Firm supporting the U.S. Government by developing and managing a diverse range of research and development collaborations for the US Army, US Navy, Department of Health and Human Services, and the Department of Energy. Carrot is exclusively focused on designing, developing, and managing online contests and open-innovation initiatives. With this acquisition, ATI is now positioned to utilize new programs that incorporate Carrot’s use of incentives and rewards systems to facilitate competition and collaboration...

Apollo Hybrid Funds to Acquire PowerGrid Services from The Sterling Group

Written by Customer Service on May 13, 2025. Posted in Mergers And Acquisitions.

Investment Will Support Leading Provider of Electric Utility Maintenance and Construction Services in its Mission to Address Growing US Power Demand and Needed Grid Improvements HARTSELLE, Ala. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE:APO) today announced that Apollo-managed funds and affiliates associated with its hybrid strategies (the “Apollo Funds”) have agreed to acquire a majority stake in PowerGrid Services (“PGS”), a leading provider of maintenance and construction services to electric utilities across the United States. The Apollo Funds will partner with existing PGS investors, including company management and The Sterling Group, to support PGS’s continued growth. PowerGrid Services keeps the lights on across America by delivering essential utility services—from routine construction and maintenance to...

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

– Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M –– Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M –– New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 –– Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC – IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, a leading global conference in liver disease. The data support ALXN1840 as a potential treatment for Wilson disease, a rare genetic disorder that causes toxic copper buildup in organs like the liver and brain. Pooled results from three clinical trials (n=255)...

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Several Key Clinical Readouts in Addition to New Study Initiations Expected in 2025 SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended March 31, 2025. Business Highlights:ART26.12:The first selective fatty acid binding protein 5 (FABP5) inhibitor to enter clinical trials completed enrollment of its Phase I safety study in healthy volunteers. Data readout remains on track for the second quarter of 2025. Newly published peer-reviewed data revealed ART26.12’s potential in psoriasis, expanding...

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-end Cash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the first quarter ended March 31, 2025. “We’re off to a strong start across our pipeline...

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

– Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson’s disease – U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson’s disease – Gained alignment with FDA on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential BLA filing – Efficacy data of rAAV8.hRKp.AIPL1 for the treatment of AIPL1-related retinal dystrophy, or LCA4, published in The Lancet, demonstrating meaningful...

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline Growth Launch of NETHERTON NOW Advocacy Initiative ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the quarter ended March 31, 2025. Quoin CEO Dr. Michael Myers said, “The first quarter of 2025 has seen continued momentum across all aspects of our business. We reported compelling data from multiple QRX003...

Brunswick Corporation Releases 2024 Corporate Sustainability Report

Written by Customer Service on May 13, 2025. Posted in Public Companies.

METTAWA, Ill., May 13, 2025 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) released its 2024 Sustainability Report today, highlighting the Company’s actions toward operating sustainably and delivering innovation and excellence in the marine industry. The full report can be accessed at: Social Responsibility (CSR) :: Brunswick Corporation (BC) To learn more about Brunswick’s commitment to leveraging strategies and initiatives related to people, products and the environment, visit: https://www.brunswick.com/overview/corporate-responsibility About Brunswick Corporation: Brunswick Corporation (NYSE: BC) is the global leader in marine recreation, delivering innovation that transforms experiences on the water and beyond. Our unique, technology-driven solutions are informed and inspired by deep consumer insights and powered by...

ECD Unleashes Its Most Powerful Defender Yet

Written by Customer Service on May 13, 2025. Posted in Public Companies.

700+ Horsepower. American Muscle. Built by Demand.KISSIMMEE, Fla., May 13, 2025 (GLOBE NEWSWIRE) — ECD Auto Design (NASDAQ: ECDA), the global leader in custom Land Rover Defenders, has added its most powerful drivetrain to date: a 700+ horsepower BLUEPRINT V8, now available as an upgrade option across the Defender lineup—and for the first time, also as a performance option for Range Rover Classic builds. This engine isn’t a gimmick. It’s a direct result of client demand—bringing together decades of LS-based experience, clever integration, and the visceral performance that discerning buyers crave. With the first client Defender build already in production, the 700HP option sets a new benchmark for what’s possible in a luxury SUV rooted in heritage but built for today. “We’ve worked with LS-based platforms for years, so this evolution...

Month: May 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals